


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (currently amended) The use of a compound of formula (I)



[(]wherein R is a C₁₆₋₂₄ unsaturated hydrocarbon group optionally interrupted α , β , γ , or δ to the carbonyl group by a heteroatom or group of heteroatoms selected from S, O, N, SO, SO₂ said hydrocarbon group comprising at least 5 non-conjugated double bonds; and X is an electron withdrawing group[)] in the manufacture of a medicament for the treatment of psoriasis.

2. (original) Use as claimed in claim 1 wherein said hydrocarbon group has 5 to 7 double bonds.

3. (currently amended) Use as claimed in claim 1 ~~claim 2~~ wherein said hydrocarbon group comprises 5 double bonds.

4. (currently amended) Use as claimed in claim 1 ~~claims 1 to 3~~ wherein no double bond is conjugated with the carbonyl group.

5. (currently amended) Use as claimed in claim 1 ~~any one of claims 1 to 4~~ wherein all double bonds are in the cis configuration.


6. (currently amended) Use as claimed in claim 1 ~~any one of claims 1 to 4~~ wherein all double bonds are in the cis configuration except the double bond nearest the carbonyl.

7. (currently amended) Use as claimed in claim 1 ~~any one of claims 1 to 6~~ wherein the R group comprises 19 to 21 carbon atoms.

8. (currently amended) Use as claimed in claim 1 ~~any one of claims 1 to 7~~ wherein the R group comprises a heteroatom or group of heteroatoms β or γ to the carbonyl.

9. (currently amended) Use as claimed in claim 1 ~~any one of claims 1 to 8~~ wherein said heteroatom or group of heteroatoms is O, S or SO.


10. (currently amended) Use as claimed in claim 1 ~~any one of claims 1 to 9~~ wherein the RCOX group is:




11. (currently amended) Use as claimed in claim 1 ~~any one of claims 1 to 10~~ wherein X is a O-C₁₋₆ alkyl, CN, CO₂-C₁₋₆ alkyl, phenyl, CHal₃, CHal₂H, CHalH₂ wherein Hal represents a halogen.

12. (currently amended) Use as claimed in claim 1 ~~claim 11~~ wherein X is CHal₃.

13. (original) Use as claimed in claim 1 wherein RCOX is




14. (currently amended) A method of treating psoriasis comprising administering to an animal an effective amount of a compound of formula (I)



[()wherein R is a C₁₆₋₂₄ unsaturated hydrocarbon group optionally interrupted α , β , γ , or δ to the carbonyl group by a heteroatom or group of heteroatoms selected from S, O, N, SO, SO₂ said hydrocarbon group comprising at least 5 non-conjugated double bonds; and

X is an electron withdrawing group[]].


15. (currently amended) Use of a compound of formula (I)



[()wherein R is a C₁₆₋₂₄ unsaturated hydrocarbon group optionally interrupted α , β , γ , or δ to the carbonyl group by a heteroatom or group of heteroatoms selected from S, O, N, SO, SO₂ said hydrocarbon group comprising at least 5 non-conjugated double bonds; and

X is an electron withdrawing group[]] for use in the manufacture of a medicament for inhibiting the enzyme IVA PLA₂.

16. (currently amended) A pharmaceutical composition comprising a compound of formula (I)



[()wherein R is a C₁₆₋₂₄ unsaturated hydrocarbon group optionally interrupted α , β , γ , or δ to the carbonyl group by a heteroatom or group of heteroatoms selected from S, O, N, SO, SO₂ said hydrocarbon group comprising at least 5 non-conjugated double bonds; and

X is an electron withdrawing group[]] and a pharmaceutically acceptable excipient.

ATTORNEY DOCKET NO. 04150.0014U1
International Application No. PCT/GB03/00364


Remarks

The specification is amended herein to update the priority claim for this application and to include the abstract as a separate sheet in accordance with 37 CFR § 1.72.

Claims 1 through 16 are pending. The claims have been amended to remove multiple dependency. It is believed that no new matter has been added by this amendment, and Applicants respectfully request entry of same into the present application.

Respectfully submitted,


NEEDLE & ROSENBERG, P.C.


Lawrence A. Villanueva
Reg. No 43,968

NEEDLE & ROSENBERG, P.C.
Customer Number 23859
(678) 420-9300
(678) 420-9301 (fax)

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. § 1.10

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as Express Mail, Label No. EL980234488US, in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.


Jason Ellis

7/23/04
Date